Prevalence of and clinical factors associated with lipoatrophy in HIV-infected Koreans receiving highly active antiretroviral therapy

Tohoku Journal of Experimental Medicine

Volumn 219, Issue 2, 2009, Pages 145-153

  Sang, Hoon Han ^a   Bum, Sik Chin ^a   Hee, Kyoung Choi ^a   So, Youn Shin ^a   Yun, Tae Chae ^a   Baek, Ji Hyeon ^a   Chang, Oh Kim ^a   Jun, Yong Choi ^a   Young, Goo Song ^a   Hyun, Chul Lee ^a   June, Myung Kim ^a  

^a Yonsei University College of Medicine   (South Korea)

Author keywords

Highly active antiretroviral therapy; HIV; Korea; Lipoatrophy; Stavudine

Indexed keywords

CHOLESTEROL; DIDANOSINE; LIPID; PROTEINASE INHIBITOR; RNA DIRECTED DNA POLYMERASE INHIBITOR; STAVUDINE; ZIDOVUDINE;

ADULT; ANAMNESIS; ARTICLE; CHOLESTEROL BLOOD LEVEL; CLINICAL FEATURE; CONTROLLED STUDY; DIABETES MELLITUS; FEMALE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; KOREA; LIPOATROPHY; MAJOR CLINICAL STUDY; MALE; PATIENT MONITORING; PHYSICAL EXAMINATION; PREVALENCE; SEX RATIO; TREATMENT DURATION;

ADULT; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; ASIAN CONTINENTAL ANCESTRY GROUP; FEMALE; HIV INFECTIONS; HUMANS; LIPODYSTROPHY; MALE; MIDDLE AGED; PREVALENCE; REGRESSION ANALYSIS; REPUBLIC OF KOREA;

EID: 70449679037     PISSN: 00408727     EISSN: 13493329     Source Type: Journal    
DOI: 10.1620/tjem.219.145     Document Type: Article

References (42)

1. Ammassari, A., Antinori, A., Cozzi-Lepri, A., Trotta, M.P., Nasti, G., Ridolfo, A.L., Mazzotta, F., Wu, A.W., d'Arminio Monforte, A. & Galli, M. (2002) Relationship between HAART adherence and adipose tissue alterations. J. Acquir. Immune Defic. Syndr., 31 Suppl 3, S140-144.
2. Bacchetti, P., Gripshover, B., Grunfeld, C., Heymsfield, S., McCreath, H., Osmond, D., Saag, M., Scherzer, R., Shlipak, M. & Tien, P. (2005) Fat distribution in men with HIV infection. J. Acquir. Immune Defic. Syndr., 40, 121-131.
3. Bergersen, B.M., Schumacher, A., Sandvik, L., Bruun, J.N. & Birkeland, K. (2006) Important differences in components of the metabolic syndrome between HIV-patients with and without highly active antiretroviral therapy and healthy controls. Scand. J. Infect. Dis., 38, 682-689.
4. Brown, T.T. (2008) Approach to the human immunodeficiency virus-infected patient with lipodystrophy. J. Clin. Endocrinol. Metab., 93, 2937-2945.
5. Carr, A., Emery, S., Law, M., Puls, R., Lundgren, J.D. & Powderly, W.G. (2003) An objective case definition of lipodystrophy in HIV-infected adults: a case-control study. Lancet, 361, 726-735.
6. Centers for Disease Control and Prevention. (1987) Revision of the CDC surveillance case definition for acquired immunodeficiency syndrome. Council of State and Territorial Epidemiologists; AIDS Program, Center for Infectious Diseases. MMWR Morb. Mortal. Wkly. Rep., 36 Suppl 1, 1S-15S.
7. Centers for Disease Control and Prevention. (1992) 1993 revised classification system for HIV infection and expanded surveillance case definition for AIDS among adolescents and adults. MMWR Recomm. Rep., 41, 1-19.
8. Chang, K.H., Kim, J.M., Song, Y.G., Hong, S.K., Lee, H.C. & Lim, S.K. (2002) Does race protect an oriental population from developing lipodystrophy in HIV-infected individuals on HAART? J. Infect., 44, 33-38.
9. Chen, D., Misra, A. & Garg, A. (2002) Clinical review 153: Lipodystrophy in human immunodeficiency virus-infected patients. J. Clin. Endocrinol. Metab., 87, 4845-4856.
10. Chuapai, Y., Kiertiburanakul, S., Malathum, K. & Sungkanuparph, S. (2007) Lipodystrophy and dyslipidemia in human immunodeficiency virus-infected Thai patients receiving antiretroviral therapy. J. Med. Assoc. Thai., 90, 452-458.
11. Estrada, V., Martinez-Larrad, M.T., Gonzalez-Sanchez, J.L., de Villar, N.G., Zabena, C., Fernandez, C. & Serrano-Rios, M. (2006) Lipodystrophy and metabolic syndrome in HIV-infected patients treated with antiretroviral therapy. Metabolism, 55, 940-945. (Pubitemid 43902897)
12. Fernandes, A.P., Sanches, R.S., Mill, J., Lucy, D., Palha, P.F. & Dalri, M.C. (2007) Lipodystrophy syndrome associated with antiretroviral therapy in HIV patients: considerations for psychosocial aspects. Rev. Lat. Am. Enfermagem, 15, 1041-1045.
13. Friedewald, W.T., Levy, R.I. & Fredrickson, D.S. (1972) Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin. Chem., 18, 499-502.
14. Galli, M., Ridolfo, A.L., Adorni, F., Gervasoni, C., Ravasio, L., Corsico, L., Gianelli, E., Piazza, M., Vaccarezza, M., d'Arminio Monforte, A. & Moroni, M. (2002) Body habitus changes and metabolic alterations in protease inhibitor-naive HIV-1-infected patients treated with two nucleoside reverse transcriptase inhibitors. J. Acquir. Immune Defic. Syndr., 29, 21-31.
15. Grinspoon, S. & Carr, A. (2005) Cardiovascular risk and body-fat abnormalities in HIV-infected adults. N. Engl. J. Med., 352, 48-62.
16. Grinspoon, S.K. (2005) Metabolic syndrome and cardiovascular disease in patients with human immunodeficiency virus. Am. J. Med., 118 Suppl 2, 23S-28S.
17. Haubrich, R.H., Riddler, S.A., DiRienzo, A.G., Komarow, L., Powderly, W.G., Klingman, K., Garren, K.W., Butcher, D.L., Rooney, J.F., Haas, D.W., Mellors, J.W. & Havlir, D.V. (2009) Metabolic outcomes in a randomized trial of nucleoside, non-nucleoside and protease inhibitor-sparing regimens for initial HIV treatment. AIDS 23, 1109-1118.
18. Jacobson, D.L., Knox, T., Spiegelman, D., Skinner, S., Gorbach, S. & Wanke, C. (2005) Prevalence of, evolution of, and risk factors for fat atrophy and fat deposition in a cohort of HIV-infected men and women. Clin. Infect. Dis., 40, 1837-1845.
19. Katz, A., Nambi, S.S., Mather, K., Baron, A.D., Follmann, D.A., Sullivan, G. & Quon, M.J. (2000) Quantitative insulin sensitivity check index: a simple, accurate method for assessing insulin sensitivity in humans. J. Clin. Endocrinol. Metab., 85, 2402-2410.
20. Law, M., Puls, R., Cheng, A.K., Cooper, D.A. & Carr, A. (2006) Evaluation of the HIV lipodystrophy case definition in a placebo-controlled, 144-week study in antiretroviral-naive adults. Antivir. Ther., 11, 179-186.
21. Lichtenstein, K.A., Ward, D.J., Moorman, A.C., Delaney, K.M., Young, B., Palella, F.J., Jr., Rhodes, P.H., Wood, K.C. & Holmberg, S.D. (2001) Clinical assessment of HIV-associated lipodystrophy in an ambulatory population. AIDS, 15, 1389-1398. (Pubitemid 32662290)
22. Mallewa, J.E., Wilkins, E., Vilar, J., Mallewa, M., Doran, D., Back, D. & Pirmohamed, M. (2008) HIV-associated lipodystrophy: a review of underlying mechanisms and therapeutic options. J. Antimicrob. Chemother., 62, 648-660.
23. Mangili, A., Jacobson, D.L., Gerrior, J., Polak, J.F., Gorbach, S.L. & Wanke, C.A. (2007) Metabolic syndrome and subclinical atherosclerosis in patients infected with HIV Clin. Infect. Dis., 44, 1368-1374.
24. Matthews, D.R., Hosker, J.P., Rudenski, A.S., Naylor, B.A., Treacher, D.F. & Turner, R.C. (1985) Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia, 28, 412-419. (Pubitemid 15018832)
25. Milinkovic, A. & Martinez, E. (2005) Current perspectives on HIV-associated lipodystrophy syndrome. J. Antimicrob. Chemother., 56, 6-9.
26. O'Leary, D.H. & Polak, J.F. (2002) Intima-media thickness: a tool for atherosclerosis imaging and event prediction. Am. J. Cardiol., 90, 18L-21L.
27. Paton, N.I., Earnest, A., Ng, Y.M., Karim, F. & Aboulhab, J. (2002) Lipodystrophy in a cohort of human immunodeficiency virus-infected Asian patients: prevalence, associated factors, and psychological impact. Clin. Infect. Dis., 35, 1244-1249.
28. Pignoli, P., Tremoli, E., Poli, A., Oreste, P. & Paoletti, R. (1986) Intimal plus medial thickness of the arterial wall: a direct measurement with ultrasound imaging. Circulation, 74, 1399-1406. (Pubitemid 17189260)
29. Polsky, B., Kotler, D. & Steinhart, C. (2004) Treatment guidelines for HIV-associated wasting. HIV Clin. Trials, 5, 50-61.
30. Pujari, S.N., Dravid, A., Naik, E., Bhagat, S., Tash, K., Nadler, J.P. & Sinnott, J.T. (2005) Lipodystrophy and dyslipidemia among patients taking first-line, World Health Organization-recommended highly active antiretroviral therapy regimens in Western India. J. Acquir. Immune Defic. Syndr., 39, 199-202.
31. Ribeiro-Filho, F.F., Faria, A.N., Kohlmann, O., Jr., Ajzen, S., Ribeiro, A.B., Zanella, M.T. & Ferreira, S.R. (2001) Ultrasonography for the evaluation of visceral fat and cardiovascular risk. Hypertension, 38, 713-717.
32. Saint-Marc, T., Partisani, M., Poizot-Martin, I., Bruno, F., Rouviere, O., Lang, J.M., Gastaut, J.A. & Touraine, J.L. (1999) A syndrome of peripheral fat wasting (lipodystrophy) in patients receiving long-term nucleoside analogue therapy. AIDS, 13, 1659-1667.
33. Sutinen, J. (2005) Interventions for managing antiretroviral therapy-associated lipoatrophy. Curr. Opin. Infect. Dis., 18, 25-33.
34. Suzuki, R., Watanabe, S., Hirai, Y., Akiyama, K., Nishide, T., Matsushima, Y., Murayama, H., Ohshima, H., Shinomiya, M., Shirai, K. & et al. (1993) Abdominal wall fat index, estimated by ultrasonography, for assessment of the ratio of visceral fat to subcutaneous fat in the abdomen. Am. J. Med., 95, 309-314.
35. Telatela, S.P., Matee, M.I. & Munubhi, E.K. (2007) Seroprevalence of hepatitis B and C viral co-infections among children infected with human immunodeficiency virus attending the paediatric HIV care and treatment center at Muhimbili National Hospital in Dar-es-Salaam, Tanzania. BMC Public Health, 7, 338.
36. van Griensven, J., De Naeyer, L., Mushi, T., Ubarijoro, S., Gashumba, D., Gazille, C. & Zachariah, R. (2007) High prevalence of lipoatrophy among patients on stavudine-containing first-line antiretroviral therapy regimens in Rwanda. Trans. R. Soc. Trop. Med. Hyg., 101, 793-798.
37. Waters, L. & Nelson, M. (2007) Long-term complications of antiretroviral therapy: lipoatrophy. Int. J. Clin. Pract., 61, 999-1014.
38. Wierzbicki, A.S., Purdon, S.D., Hardman, T.C., Kulasegaram, R. & Peters, B.S. (2008) HIV lipodystrophy and its metabolic consequences: implications for clinical practice. Curr. Med. Res. Opin., 24, 609-624.
39. Wohl, D.A., McComsey, G., Tebas, P., Brown, T.T., Glesby, M.J., Reeds, D., Shikuma, C., Mulligan, K., Dube, M., Wininger, D., Huang, J., Revuelta, M., Currier, J., Swindells, S., Fichtenbaum, C., Basar, M., Tungsiripat, M., Meyer, W., Weihe, J. & Wanke, C. (2006) Current concepts in the diagnosis and management of metabolic complications of HIV infection and its therapy. Clin. Infect. Dis., 43, 645-653.
40. World Health Organization. (2006) International Statistical Classification of Diseases and Related Health Problems. 10th Revision, 2nd ed. Geneva. World Health Organization.
41. Yanase, T., Nasu, S., Mukuta, Y., Shimizu, Y., Nishihara, T., Okabe, T., Nomura, M., Inoguchi, T. & Nawata, H. (2006) Evaluation of a new carotid intima-media thickness measurement by B-mode ultrasonography using an innovative measurement software, intimascope. Am. J. Hypertens., 19, 1206-1212. (Pubitemid 44856248)
42. Zureik, M., Touboul, P.J., Bonithon-Kopp, C., Courbon, D., Ruelland, I. & Ducimetiere, P. (1999) Differential association of common carotid intima-media thickness and carotid atherosclerotic plaques with parental history of premature death from coronary heart disease: the EVA study. Arterioscler Thromb. Vasc. Biol., 19, 366-371.